AbbVie Stock Hovers Just Below 52-Week High of $262.10 as Momentum Holds

By TrendSpider Editor

ABBV market update based on latest price_mover data.

AbbVie Stock Hovers Just Below 52-Week High of $262.10 as Momentum Holds

AbbVie Inc. (ABBV) is trading at $256.915 on Tuesday, July 28, 2026, essentially flat on the session with a 0.00% price change, yet the stock remains within striking distance of its 52-week high of $262.10. That ceiling was tested as recently as yesterday, when shares touched $262.10 intraday before pulling back slightly. Against a 52-week low of $187.62, the current price represents a gain of roughly 37% from the bottom of that range, underscoring the sustained upward trajectory AbbVie has carved out over the past year.

Key Drivers of the ABBV Stock Move

AbbVie's sustained strength near multi-year highs reflects broader confidence in the company's pharmaceutical portfolio and pipeline execution. The stock has spent considerable time in the upper half of its $187.62 to $262.10 annual range, and the fact that it tagged the 52-week high during yesterday's session before settling at $256.915 today suggests the market is carefully evaluating whether a sustained breakout is warranted. Traders will be watching for a definitive close above $262.10 as confirmation of the next leg higher, while any reversal from current levels would bring the prior session's low of $256.787 into focus as immediate support.

ABBV Seasonality

Late July has historically been an active period for large-cap pharmaceutical names, as many report second-quarter earnings during this window. With ABBV trading near its 52-week high heading into this period, any earnings-related catalyst in the coming days could serve as either a breakout trigger or a sell-the-news event for momentum traders.

ABBV Relative Performance

Trading at $256.915 and within 2% of its 52-week high of $262.10, AbbVie is demonstrating meaningful relative strength. The stock's 52-week range spans from $187.62 to $262.10, a spread of $74.48, and the current price sits in approximately the top 93% of that range. This positioning compares favorably to broader large-cap healthcare peers that have faced more pressure in 2026, suggesting AbbVie continues to attract capital as a relative safe haven within the sector.

More on ABBV

Latest Market News